Welcome to NGC. Skip directly to: Search Box, Navigation, Content.


Brief Summary

GUIDELINE TITLE

Type I diabetes practice guidelines.

BIBLIOGRAPHIC SOURCE(S)

  • International Diabetes Center. Type 1 diabetes practice guidelines. Minneapolis (MN): International Diabetes Center; 2003. 1 p.

GUIDELINE STATUS

This is the current release of the guideline.

This guideline updates a previous version: International Diabetes Center, Institute for Research and Education. Staged diabetes management: a systematic approach. Minneapolis (MN): Matrex, International Diabetes Center; 2000. Type 1 diabetes practice guidelines. p. 133-71.

BRIEF SUMMARY CONTENT

 
RECOMMENDATIONS
 EVIDENCE SUPPORTING THE RECOMMENDATIONS
 IDENTIFYING INFORMATION AND AVAILABILITY
 DISCLAIMER

 Go to the Complete Summary

RECOMMENDATIONS

MAJOR RECOMMENDATIONS

The following is an outline of practice guidelines for management of type 1 diabetes mellitus. A detailed management plan and accompanying DecisionPaths can be found in the original guidelines.

Diagnosis

Majority younger than 30 years old and not obese

Plasma Blood Glucose

Casual >200 mg/dL plus symptoms, fasting >126 mg/dL, or oral glucose tolerance test (OGTT) 2 hour glucose value >200 mg/dL; if acute metabolic decompensation (positive ketones), make diagnosis immediately; in the absence of acute metabolic decompensation, confirm with casual or fasting plasma glucose within 24 hours.

Symptoms

Common: Increased urination, thirst, and appetite; nocturia; weight loss

Occasional: Blurred vision, urinary tract infection, yeast infection, fatigue, acute abdominal pain, flu-like symptoms

Urine Ketones

Usually positive, with or without diabetic ketoacidosis

Treatment Options

Insulin Stages 2, 3A, 4A, 3B, or pump synchronized with food plan and exercise program (see Type 1: Master DecisionPath in the original guideline document.) These patients require insulin therapy and should not be treated with an oral agent.

Targets

Blood Pressure

Less than 130/80 mmHg

Lipids

Low-density lipoprotein (LDL) less than 100 mg/dL, high-density lipoprotein (HDL) >40 mg/dL, Triglyceride less than 150 g/dL

Self-Monitored Blood Glucose

  • More than 50% of self-monitored blood glucose values should be within target range
  • Age younger than 6 years: 100 to 200 mg/dL pre-meal and bedtime
  • Age 6 to 12 years: 80 to 180 mg/dL pre-meal and bedtime
  • Age older than 12 years: 80 to 140 mg/dL pre-meal; <160 mg/dL 2 hours after start of meal; 100 to 160 mg/dL at bedtime
  • No severe (assisted) or nocturnal hypoglycemia

Adjust pre-meal target upwards if hypoglycemia unawareness or repeated severe hypoglycemia occurs.

Hemoglobin A1c (HbA1c)

  • Age younger than 6 years: Within 2.5% points of upper limit of normal (e.g., normal 6%; target <8.5%)
  • Age 6 to 12 years: Within 2% points of upper limit of normal (e.g., normal 6%; target <8.0%)
  • Age older than 12 years: Within 1.0% points of upper limit of normal (e.g., normal 6%; target <7.0%)
  • Use hemoglobin A1c to verify self-monitored blood glucose data or to adjust therapy when data unavailable

Monitoring

Hemoglobin A1c (HbA1c)

Frequency: every 3 to 4 months

Self-Monitored Blood Glucose

Minimum 4 times per day (before meals, 2 hours after start of meal, and bedtime) Check 3 a.m. as needed (AM hyperglycemia, nocturnal hypoglycemia)

Method

Meter and log book

Urine Ketones

Check if unexplained blood glucose >240 mg/dL on 2 consecutive occasions, or if any illness or infection present

Growth and Development

Normal, as determined using anthropometric scales/growth charts

Follow-Up

Weekly

During Start and early Adjust Phase

Monthly

Office visit during Adjust Phase (weekly phone contact may be necessary)

Every 3 Months

Hypoglycemia, medications, weight, height, growth rate, food plan and exercise, blood pressure, self-monitored blood glucose data (download and check meter), hemoglobin A1c, eye screen, foot screen, diabetes/nutrition continuing education, preconception planning for women with child bearing potential, smoking cessation counseling, aspirin therapy

Yearly

In addition to the 3 month follow-up, complete the following: history and physical, dental examination, fasting lipid profile within 6 months of diagnosis.

In patients older than age 12 with diabetes for 5 years, complete the following: albuminuria/proteinuria screen, dilated eye examination, neurologic assessment, complete foot examination (pulses, nerves, and inspection), patient satisfaction evaluation.

Complications Surveillance

Cardiovascular, renal, retinal, neurological, foot, oral, and dermatological

CLINICAL ALGORITHM(S)

Algorithms are provided for management of type 1 diabetes mellitus in the form of a Master DecisionPath as well as separate detailed DecisionPaths for:

  • Screening and Diagnosis
  • Medical Nutrition Therapy
  • Insulin Pump/Start
  • Preconception Diabetes Management
  • Multidisciplinary Approach to Management of Pregnancy
  • Exercise Plan
  • Insulin Administration Adherence
  • Psychological and Social Assessment

EVIDENCE SUPPORTING THE RECOMMENDATIONS

TYPE OF EVIDENCE SUPPORTING THE RECOMMENDATIONS

The type of supporting evidence is not specifically stated for each recommendation. However, throughout the guideline document, the evidence used as the basis for the recommendations is discussed.

IDENTIFYING INFORMATION AND AVAILABILITY

BIBLIOGRAPHIC SOURCE(S)

  • International Diabetes Center. Type 1 diabetes practice guidelines. Minneapolis (MN): International Diabetes Center; 2003. 1 p.

ADAPTATION

Not applicable: The guideline was not adapted from another source.

DATE RELEASED

2000 (revised 2003)

GUIDELINE DEVELOPER(S)

International Diabetes Center - Private Nonprofit Organization

GUIDELINE DEVELOPER COMMENT

The International Diabetes Center is part of the Institute for Research and Education HealthSystem Minnesota. HealthSystem Minnesota, an integrated care system, also includes Methodist Hospital, Park Nicollet Clinic, and The Foundation.

The International Diabetes Center is a World Health Organization (WHO) Collaborating Center for Diabetes Education, Translation and Computer Technology.

SOURCE(S) OF FUNDING

This publication is supported by an unrestricted educational grant from Becton Dickinson and Company.

GUIDELINE COMMITTEE

Not stated

COMPOSITION OF GROUP THAT AUTHORED THE GUIDELINE

Authors: Roger S. Mazze, PhD, Ellie S. Strock, RN, ANP, CDE; Gregg D. Simonson, PhD, Richard M. Bergenstal, MD, Donnell D. Etzwiler, MD

FINANCIAL DISCLOSURES/CONFLICTS OF INTEREST

Not stated

GUIDELINE STATUS

This is the current release of the guideline.

This guideline updates a previous version: International Diabetes Center, Institute for Research and Education. Staged diabetes management: a systematic approach. Minneapolis (MN): Matrex, International Diabetes Center; 2000. Type 1 diabetes practice guidelines. p. 133-71.

GUIDELINE AVAILABILITY

AVAILABILITY OF COMPANION DOCUMENTS

None available

PATIENT RESOURCES

None available

NGC STATUS

This summary was completed by ECRI on May 21, 2001. This summary was updated by ECRI on February 18, 2004. The information was verified by the guideline developer on March 11, 2004.

COPYRIGHT STATEMENT

This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions.

Copyright 2000. International Diabetes Center, Institute for Research and Education. All rights reserved. No part of these Guidelines may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, photocopying, recording or otherwise, without prior written permissions of the International Diabetes Center. These Guidelines should not be interpreted as including all available and proper methods of diabetes care. The decision regarding any specific treatment modality must be made by the health care professional with consideration of the particular circumstances presented by the patient and the needs and resources particular to the community or institution.

DISCLAIMER

NGC DISCLAIMER

The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.

All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.

Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at http://www.guideline.gov/about/inclusion.aspx .

NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.

Readers with questions regarding guideline content are directed to contact the guideline developer.


 

 

   
DHHS Logo